Results 121 to 130 of about 10,157,624 (223)

Extranodal Non-Hodgkin’s Lymphoma of the Oral Cavity: A Case Report

open access: yesIranian Journal of Medical Sciences, 2017
Lymphomas are solid malignant tumors having a wide spectrum of clinical and pathological features. Non-Hodgkin’s lymphoma (NHL) is a subtype of lymphoma with two-thirds of the cases presenting as lymph node enlargement.
Babyamma Raghavan Varun   +3 more
doaj  

The synergistic interaction between CD20 monoclonal antibodies and Histone Deacetylase inhibitors in B cell Non Hodgkin’s Lymphoma

open access: yes, 2010
Recent improvements in molecular sub typing of Non Hodgkin’s lymphomashave resulted in targeted therapies becoming incorporated into treatmentparadigms.
Nolan, David Francis Luke
core   +1 more source

Prognostic impact of blood Epstein–Barr virus‐DNA in patients with peripheral T‐cell lymphoma, not otherwise specified

open access: yesBritish Journal of Haematology, EarlyView.
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon   +14 more
wiley   +1 more source

Comorbid conditions after allogeneic haematopoietic stem cell transplantation in young adults in Germany—A prospective, multicentre trial

open access: yesBritish Journal of Haematology, EarlyView.
Summary Young adults (YA) are particularly affected by comorbid conditions following allogeneic haematopoietic stem cell transplantation (alloHSCT), as they have to live with them for many years. This is the first multicentre prospective study investigating sequelae after alloHSCT in YA in Germany. In total, 107 patients who survived relapse‐free until
Pauline Rocke   +9 more
wiley   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend   +16 more
wiley   +1 more source

Risk of Type II Diabetes Mellitus Among B-Cell Non-Hodgkin's Lymphoma Survivors. [PDF]

open access: yesCancer Med
Chi E   +9 more
europepmc   +1 more source

The association between inborn errors of immunity and Hodgkin lymphoma—A register‐based case–control study in Sweden

open access: yesBritish Journal of Haematology, EarlyView.
Summary Immune dysfunction is implicated in the aetiology of Hodgkin lymphoma (HL), but the association between inborn errors of immunity (IEI) and HL remains poorly understood. We conducted a retrospective, register‐based case–control study in Sweden over five decades to investigate the relationship between IEI and HL. Individuals diagnosed with HL in
Agnes Winsa   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy